CALT:NSD-Calliditas Therapeutics AB (publ) (USD)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | NSD

Last Closing Price

USD 28.03

Change

0.00 (0.00)%

Market Cap

USD 0.70B

Volume

0.06M

Average Target Price

USD 52.00 (+85.52%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Calliditas Therapeutics AB (publ) operates as a biopharmaceutical company in Stockholm, Sweden. It focuses on identifying, developing, and commercializing pharmaceutical products for patients with unmet medical needs. The company's lead product candidate is Nefecon, a unique formulation optimized to combine a time lag effect with a concentrated release of the active substance budesonide, within a designated target area. This patented, locally acting formulation is intended for treatment of patients with the inflammatory renal disease IgA nephropathy. Calliditas Therapeutics AB (publ) also intends to take Nefecon through a global Phase 3 study to commercialization. The company was founded in 2004 and is headquartered in Stockholm, Sweden.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-05-09 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
CGC Canopy Growth Corporation

N/A

USD9.58B N/A N/A
MYL Mylan N.V

N/A

USD8.59B 30.73 11.86
TLRY Tilray, Inc

N/A

USD7.22B N/A N/A
APHA Tilray, Inc

N/A

USD6.86B 60.60 454.68
MNTA Momenta Pharmaceuticals, Inc

N/A

USD6.24B N/A N/A
CRON Cronos Group Inc

N/A

USD2.83B 37.00 N/A
PCRX Pacira BioSciences, Inc

N/A

USD2.78B 19.02 40.01
ORGO Organogenesis Holdings Inc

N/A

USD2.71B 132.19 72.85
IRWD Ironwood Pharmaceuticals, Inc

N/A

USD1.78B 12.22 12.61
SUPN Supernus Pharmaceuticals, Inc

N/A

USD1.56B 14.22 8.94

ETFs Containing CALT

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -17.53% 25% F 16% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -17.53% 25% F 16% F
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) N/A N/A N/A N/A N/A
Risk Adjusted Return N/A N/A N/A N/A N/A
Market Capitalization 0.70B 72% C- 57% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio -99,999.99 100% A+ 95% A
Price/Book Ratio 4.85 42% F 34% F
Price / Cash Flow Ratio -2.26 33% F 61% D-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -42.70% 55% F 25% F
Return on Invested Capital -38.04% 40% F 21% F
Return on Assets -19.75% 40% F 20% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 0.60 87% B+ 78% C+
Short Percent N/A N/A N/A N/A N/A
Beta 1.53 32% F 27% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative earnings

The company had negative total earnings in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector